Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Cancer Immunol Res. 2014 Nov 4;3(2):136–148. doi: 10.1158/2326-6066.CIR-14-0036

Figure 2. Tasquinimod in combination with vaccine or TTS improves T-cell immune responses.

Figure 2

Splenocytes isolated from CR Myc-CaP tumor-bearing mice were stimulated with A. PMA and Ionomycin for 5 hours in the presence of BFA for IFNγ production, or B. on CD3- and CD28-coated plates for 72 hours for Granzyme B production (BFA was added during the last 5 hours). C. Splenocytes (left panel) or purified CD8+ T cells (right panel) from CR Myc-CaP tumor-bearing mice were co-cultured with DIO-labeled tumor cells in different ratios for 5 hours. Propidium iodide was added at the end of incubation to detect tumor cell death. D. FACS analysis of tumor-infiltrating T cells performed at the endpoint of the experiment depicted in Fig. 1B. E-G. FACS analysis of infiltrating T cells in B16-h5T4 tumors at different time points. 5T4Fab-SEA was administered on days 9-11. (*p < 0.05; **p < 0.01; ***p<0.001, t-test. Error bars indicate s.e.m.)